Serotonergic Syndrome Risk with Tramadol

Mechanism of Action and Risk Factors

Tramadol is an atypical opioid with a dual mechanism of action, acting as a weak mu-opioid receptor agonist and inhibiting both norepinephrine and serotonin reuptake, according to the National Comprehensive Cancer Network 1, 2, 3
The use of tramadol should be cautious or avoided in patients taking other serotonergic medications, such as TCAs, SSRIs, and MAOIs, due to the risk of serotonin syndrome, as recommended by the National Comprehensive Cancer Network 1, 2, 3

Serotonin syndrome can be triggered when serotonergic medications are combined, with symptoms developing within 24-48 hours after combining medications, and presents with a characteristic triad of symptoms, including mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, according to the American Academy of Child and Adolescent Psychiatry 4, 5
Discontinuation of all serotonergic agents is essential in moderate to severe serotonin syndrome, and supportive care with continuous cardiac monitoring is required, as recommended by the American Academy of Child and Adolescent Psychiatry 4, 5

When prescribing tramadol, the maximum recommended daily dose is 400 mg for immediate-release formulations or 300 mg/day for extended-release formulations in adults with normal hepatic and renal function, according to the National Comprehensive Cancer Network 1, 2, 3
Special caution should be exercised when combining tramadol with other medications that increase serotonin levels, as recommended by the Mayo Clinic 6